236 related articles for article (PubMed ID: 29727211)
41. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
42. A case of aseptic meningitis in a cetuximab-experienced patient with metastatic colon cancer.
Rohrer CL; Grullon Z; George SK; Castillo R; Karasiewicz K
J Oncol Pharm Pract; 2018 Dec; 24(8):632-633. PubMed ID: 29157147
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
44. Clinical management of cutaneous toxicity of anti-EGFR agents.
Monti M; Motta S
Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
[TBL] [Abstract][Full Text] [Related]
45. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
46. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
Mancl EE; Kolesar JM; Vermeulen LC
Am J Health Syst Pharm; 2009 Dec; 66(23):2105-12. PubMed ID: 19923311
[TBL] [Abstract][Full Text] [Related]
47. Navigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix.
Sangaré L; Divita A; Rehn M; McNamara M; Lowe KA
Support Care Cancer; 2021 Nov; 29(11):6731-6740. PubMed ID: 33973081
[TBL] [Abstract][Full Text] [Related]
48. Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients.
Chularojanamontri L; Tuchinda P; Likitwattananurak C; Pongparit K; Rujitharanawong C; Ithimakin S; Kulthanan K
Asian Pac J Allergy Immunol; 2019 Mar; 37(1):12-18. PubMed ID: 29549700
[TBL] [Abstract][Full Text] [Related]
49. Cutaneous reactions to chemotherapy and their management.
Wyatt AJ; Leonard GD; Sachs DL
Am J Clin Dermatol; 2006; 7(1):45-63. PubMed ID: 16489842
[TBL] [Abstract][Full Text] [Related]
50. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.
Kubo A; Hashimoto H; Takahashi N; Yamada Y
World J Gastroenterol; 2016 Jan; 22(2):887-94. PubMed ID: 26811634
[TBL] [Abstract][Full Text] [Related]
51. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
[TBL] [Abstract][Full Text] [Related]
52. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
Rothschild SI; Betticher D; Zenhäusern R; Anchisi S; von Moos R; Pless M; Moosmann P; Popescu RA; Calderoni A; Dressler M; Rauch D; Pederiva S; Woelky R; Papet C; Bühler V; Borner M
Cancer Chemother Pharmacol; 2019 Oct; 84(4):881-889. PubMed ID: 31444619
[TBL] [Abstract][Full Text] [Related]
53. Skin Toxicities During Colorectal Cancer Chemotherapy: Incidence and Pearls of Treatment in Our Experience.
Panariello L; Donnarumma M; Iaffaioli RV; Chiodini P; Annunziata MC; Peduto T; Fabbrocini G
Clin Colorectal Cancer; 2020 Dec; 19(4):e235-e242. PubMed ID: 32665093
[TBL] [Abstract][Full Text] [Related]
54. Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts.
De Tursi M; Zilli M; Carella C; Auriemma M; Lisco MN; Di Nicola M; Di Martino G; Natoli C; Amerio P
Onco Targets Ther; 2017; 10():3007-3015. PubMed ID: 28670133
[TBL] [Abstract][Full Text] [Related]
55. Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study.
Duffour J; Thézenas S; Dereure O; Garcin A; Caron J; Samalin E; Portales F; Fiess C; Chalbos P; Gestin-Boyer C; Ychou M; Guillot B
Eur J Cancer; 2010 Dec; 46(18):3169-74. PubMed ID: 20417092
[TBL] [Abstract][Full Text] [Related]
56. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis.
Hsieh MC; Wu CF; Chen CW; Shi CS; Huang WS; Kuan FC
Sci Rep; 2018 Feb; 8(1):2047. PubMed ID: 29391418
[TBL] [Abstract][Full Text] [Related]
57. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial.
Tsutsui K; Kikuchi K; Nozawa K; Takashima A; Tsuchiyama K; Namikawa K; Aiba S; Yamazaki N
J Dermatol; 2021 Jul; 48(7):1077-1080. PubMed ID: 33682955
[TBL] [Abstract][Full Text] [Related]
59. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.
Potthoff K; Hofheinz R; Hassel JC; Volkenandt M; Lordick F; Hartmann JT; Karthaus M; Riess H; Lipp HP; Hauschild A; Trarbach T; Wollenberg A
Ann Oncol; 2011 Mar; 22(3):524-535. PubMed ID: 20709812
[TBL] [Abstract][Full Text] [Related]
60. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
